{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:59:35Z","timestamp":1790269175605,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoiotech.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immuno-Oncology and Technology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.iotech.2026.101609","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T17:51:59Z","timestamp":1786384319000},"page":"101609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Management of systemic lupus erythematosus and antiphospholipid syndrome during CAR-T therapy: insights from two clinical cases"],"prefix":"10.1016","volume":"31","author":[{"given":"C.","family":"Normand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Almaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Stadelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5804-4397","authenticated-orcid":false,"given":"M.","family":"Goodyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8439-6679","authenticated-orcid":false,"given":"A.I. Martin","family":"Quesada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0283-3047","authenticated-orcid":false,"given":"A.","family":"Mulvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9705-4168","authenticated-orcid":false,"given":"P.","family":"Szturz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-4718","authenticated-orcid":false,"given":"B.","family":"Gentner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Trueb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Arber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1135-2377","authenticated-orcid":false,"given":"E.","family":"Ghisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9410-1812","authenticated-orcid":false,"given":"M.","family":"Le Moine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iotech.2026.101609_bib1","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.iotech.2026.101609_bib2","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.iotech.2026.101609_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.iotech.2026.101609_bib4","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.iotech.2026.101609_bib5","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.iotech.2026.101609_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.iotech.2026.101609_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103687","article-title":"Harnessing the potential of CAR-T cell in lupus treatment: from theory to practice","volume":"23","author":"Alsuliman","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.iotech.2026.101609_bib8","first-page":"2001","article-title":"Anti-CD19 chimeric antigen receptor T cell therapy achieved rapid and sustained remission in a patient with systemic lupus erythematosus-associated refractory immune thrombocytopenia","volume":"43","author":"Zhao","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.iotech.2026.101609_bib9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.iotech.2026.101609_bib10","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.iotech.2026.101609_bib11","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.iotech.2026.101609_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.iotech.2026.101609_bib13","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.iotech.2026.101609_bib14","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1016\/j.ymthe.2024.03.030","article-title":"Need for standardization of cytokine profiling in CAR T cell therapy","volume":"32","author":"Biery","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.iotech.2026.101609_bib15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-024-01100-5","article-title":"Novel strategies to manage CAR-T cell toxicity","volume":"24","author":"Mulvey","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.iotech.2026.101609_bib16","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.iotech.2026.101609_bib17","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.annonc.2025.03.011","article-title":"Enrichment of CD7+CXCR3+ CAR T-cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma","volume":"36","author":"Bartolini","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.iotech.2026.101609_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.iotech.2026.101609_bib19","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00210-025-04425-z","article-title":"CAR T cell therapy efficacy and safety in SLE: a systematic review and pooled analysis of 47 patients across 10 studies","volume":"399","author":"Sayed","year":"2026","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.iotech.2026.101609_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152786","article-title":"CAR T-cell therapy in SLE: a systematic review","volume":"74","author":"Nordmann-Gomes","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.iotech.2026.101609_bib21","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41409-023-02086-1","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study","volume":"58","author":"Wang","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.iotech.2026.101609_bib22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jtha.2024.09.024","article-title":"Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome","volume":"23","author":"Friedberg","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.iotech.2026.101609_bib23","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41584-024-01179-5","article-title":"The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus","volume":"20","author":"D\u00f6rner","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.iotech.2026.101609_bib24","article-title":"Interferon activation in bone marrow long-lived plasma cells in systemic lupus erythematosus","volume":"15","author":"Alzamareh","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.iotech.2026.101609_bib25","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.iotech.2026.101609_bib26","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.iotech.2026.101609_bib27","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.iotech.2026.101609_bib28","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.ard.2025.06.2128","article-title":"BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis","volume":"84","author":"Hu","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.iotech.2026.101609_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1476859","article-title":"CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.iotech.2026.101609_bib30","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.iotech.2026.101609_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00281-024-01034-5","article-title":"Current advancements in cellular immunotherapy for autoimmune disease","volume":"47","author":"Berry","year":"2025","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.iotech.2026.101609_bib32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.iotech.2026.101609_bib33","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/bjh.19583","article-title":"Coagulation abnormalities associated with CAR-T-cell therapy in haematological malignancies: a review","volume":"205","author":"Peng","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.iotech.2026.101609_bib34","doi-asserted-by":"crossref","first-page":"8349","DOI":"10.3390\/ijms24098349","article-title":"Thrombotic events are unusual toxicities of chimeric antigen receptor T-cell therapies","volume":"24","author":"Schorr","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.iotech.2026.101609_bib35","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.3390\/cancers17172876","article-title":"Endothelial injury following CAR-T cell immunotherapy for hematological malignancies","volume":"17","author":"Demosthenous","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.iotech.2026.101609_bib36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/bjh.19619","article-title":"Coagulopathy in CAR-T: critical concern or mere blip?","volume":"205","author":"Galli","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.iotech.2026.101609_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102476","article-title":"Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee","volume":"69","author":"Greco","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.iotech.2026.101609_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1155222","article-title":"Pyroptosis-triggered pathogenesis: new insights on antiphospholipid syndrome","volume":"14","author":"Tan","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.iotech.2026.101609_bib39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10238-025-01790-0","article-title":"CCL22 as a diagnostic and prognostic biomarker for pediatric-onset systemic lupus erythematosus","volume":"25","author":"Chen","year":"2025","journal-title":"Clin Exp Med"},{"issue":"suppl 1","key":"10.1016\/j.iotech.2026.101609_bib40","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1182\/blood-2023-187962","article-title":"Cytokine profiling in antiphospholipid syndrome demonstrates persistent immune dysregulation and a procoagulant phenotype","volume":"142","author":"Hubben","year":"2023","journal-title":"Blood"},{"issue":"suppl 9","key":"10.1016\/j.iotech.2026.101609_bib41","article-title":"Cytokine profiles in antiphospholipid syndrome","volume":"77","author":"Liu","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.iotech.2026.101609_bib42","article-title":"Uncoupling interferons and the interferon signature explains clinical and transcriptional subsets in SLE","volume":"5","author":"G\u00f3mez-Ba\u00f1uelos","year":"2024","journal-title":"Cell Rep Med"}],"container-title":["Immuno-Oncology and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:01:00Z","timestamp":1790265660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590018826000286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"alternative-id":["S2590018826000286"],"URL":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101609","relation":{},"ISSN":["2590-0188"],"issn-type":[{"value":"2590-0188","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of systemic lupus erythematosus and antiphospholipid syndrome during CAR-T therapy: insights from two clinical cases","name":"articletitle","label":"Article Title"},{"value":"Immuno-Oncology and Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101609","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101609"}}